To Boost Or Not To Boost? Pfizer At Odds With US FDA
Pfizer Unphased By Apparent Pushback
Executive Summary
US regulators indicate that authorizing booster shots is not a priority - but Pfizer still plans to seek an EUA in the fall.
You may also be interested in...
Novavax Pins COVID-19 Hopes On Ex-US, Booster Markets
The company is planning to file with regulators in the UK, EU, Canada, Australia and New Zealand, with an emphasis on booster shots in developed markets.
ImmunityBio Sees Booster Role For Under-The-Tongue COVID-19 Vaccine
In search of a differentiated approach, ImmunityBio’s candidate aims to boostT-cell immune responses via a subcutaneous and oral vaccine combination.
Novavax’s Latecomer COVID-19 Vaccine Impresses With 90% Efficacy Result
Arriving two to three months later than planned, Novavax’s nanoparticle-based vaccine is still a welcome addition to the field, for both rich and poor countries.